Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CACI International heads into its October 15 earnings report with a fresh analyst downgrade, rebuilding short interest, and a stock that has dropped nearly 4% in a single session.
The most consequential move this week came from the Street. BNP Paribas cut CACI to Underperform on October 6, slashing its target from $675 to $540, a level well below the current price of $599.64. That same day, Citigroup moved in the opposite direction, raising its Neutral target from $648 to $689. The two actions neatly frame the debate: bulls point to a post-August re-rating after strong results, while the bear case rests on a weak FQ2 revenue print, a book-to-bill ratio of just 0.6x, and a funded backlog that has been shrinking. The mean analyst target of $730 implies meaningful upside from here, but the BNP downgrade is a reminder that not everyone believes the August surge was warranted. The broader firm direction since August has been upward, with JP Morgan raising to $715 and UBS lifting to $804 after the last print, but those moves came before the current drift lower.
Short positioning has been quietly building ahead of the release. Short interest has risen around 6.4% over the past week to roughly 4.1% of the free float, recovering ground lost over the prior month when it fell about 5.6%. The borrowing market remains relaxed: cost to borrow has eased to 0.40%, down about 14% on the week and nearly 30% over the past month. Availability is exceptionally loose at over 1,400% of short interest, with more than 14 million shares available to lend against fewer than 900,000 shorted. There is no squeeze pressure in this lending pool. The short score has edged up to 38.5, its highest reading in the past two weeks, consistent with the rebuilding trend but nowhere near alarming territory.
Options traders are positioned more bullishly than usual, which sits in contrast to the cautious analyst action. The put/call ratio has fallen to 0.27, near its 52-week low of 0.27 and well below its 20-day average of 0.32. That reading is about 0.8 standard deviations below the mean, suggesting call activity has been dominant in recent sessions. The 52-week high for the PCR was 2.02, so the current positioning represents an unusually low level of hedging demand relative to the past year. Whether that reflects confidence in the earnings setup or simply an absence of downside protection buyers is the question the October 15 print will answer.
On valuation, the stock trades at a PE of about 16.3x and an EV/EBITDA of 12.6x, with both multiples compressing modestly over the past 30 days. The 90-day EPS momentum factor score sits at 92, near the top of the universe, and the 12-month forward EPS growth score ranks at 78. Value metrics are less flattering, with the EV/EBIT factor ranking at just the 25th percentile. The bull case from management centres on fiscal 2026 revenue guidance of $9.3 billion to $9.5 billion and $281 million in year-to-date free cash flow. The bear case is more immediate: a contracting environment where CACI is winning less than it is burning through, as that 0.6x book-to-bill ratio illustrates. Closest sector peer LDOS fell 5.2% on the week, while BAH dropped 2.3%, suggesting the weakness in defence IT is broader than a CACI-specific story.
The October 15 report is the event that resolves the current tension between a rebuilding short base, a fresh bear-side downgrade, and options positioning that is close to its most bullish of the year. Earnings history adds another dimension: the last comparable print in August triggered a one-day move of nearly 20% and a five-day gain of around 29%, meaning the market has recent memory of large moves in both directions. What to watch is whether the book-to-bill ratio recovers toward 1x and whether management's full-year guidance holds, given those are the two data points the BNP downgrade rests on.
See the live data behind this article on ORTEX.
Open CACI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
